
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Physician Spend Management: How Health and Life Sciences Companies Can Simplify Compliance with Master Data Management - Siperian Whitepaper






